View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 5, 2019updated 13 Aug 2019 5:04am

Nestle-sponsored trial violates India’s Infant Milk Substitutes Act

A clinical trial sponsored by infant milk substitutes and infant foods maker Nestle has violated Indian law under the Infant Milk Substitutes (IMS) Act.

A clinical trial sponsored by infant milk substitutes and infant foods maker Nestle has violated Indian law under the Infant Milk Substitutes (IMS) Act.

The research was titled ‘Multicentric Observational Study to Observe Growth in Preterm hospitalized infants’.

The Breastfeeding Promotion Network of India (BPNI) has confirmed that Nestle India conducted clinical trials on 75 premature babies in five hospitals on substitutes for breast milk.

The trial was supported by five major hospitals in India namely, Cloud nine Hospital in Bangalore, Institute of Child Health in Kolkata, Manipal Hospital in Bangalore, Sir Ganga Ram Hospital in New Delhi, and the Calcutta Medical Research Institute in Kolkata.

The issue came to light when BPNI examined the ICMR Clinical Trial Registry maintained by the Indian Council of Medical Research (ICMR).

BPNI central coordinator Dr Arun Gupta said: “This is a gross and blatant violation of the IMS Act, and attracts the section 9.2, demanding strict action by the authorities.

“The hospital receiving such monetary or material Support need to be aware that violation of the IMS Act is a criminal offence; cognisable under IPC.”

According to the Indian law, manufacturers are prohibited from sponsoring or funding medical research or financing any part of the health care system.

BPNI has written a letter informing the Indian Ministry of Health and Family Welfare regarding the violation of the act.

The health ministry has ordered the ICMR to examine the compliant and take necessary action, as well as to screen all future trials for any infringement of the act.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU